A network meta-analysis compared GLP-1 receptor agonists to traditional anti-diabetes drugs based on hypoglycemia incidence, HbA1c goals, and more.
Researchers compared the safety and efficacy of a GLP-1 receptor agonist in patients aged 65 years or older to those under 65 years.
Does the body mass index of a diabetic patient have any effect on the efficacy of GLP-1 receptor agonists?
Can adding a GLP-1 receptor agonist to lifestyle changes improve obstructive sleep apnea management in your patients?
Clinical trials have shown that GLP-1 RAs reduce HbA1c and weight in type 2 diabetes, but are these outcomes confounded by concomitant medications?
A meta-analysis examined the effect of treatment with a GLP-1 receptor agonist on cardiovascular event risk in type 2 diabetes patients.
Unlike typical Western patients, type 2 diabetes patients in Asia tend to have lower BMIs. Does this mean responses to GLP-1 RAs differ as well?
The LEADER trial of GLP-1 RA liraglutide examined anthropometric measures of adiposity and cardiovascular risk in type 2 diabetes patients.
Does a GLP-1 receptor agonist offer the same weight-loss benefits to different racial subgroups?
How did dulaglutide measure up when compared to metformin or sitagliptin, insulin, or other GLP-1 receptor agonists?